Inox wind
Promoter entity IWEL may sell up to 5% stake soon. The block deal may happen in the range of 148 to 150 per share. (Source – CNBC Awaaz)
On 27th May, 2024, Inox wind’s shares closed 0.7% lower at Rs 163.80 apiece.
Q4FY24 results update
| Revenue | 528 (vs 191 YOY) |
| EBITDA | 123 (vs -27 YOY) |
| PAT | 37 (vs -119 YOY) |
| EPS | 0.36 (vs -0.90 YOY) |
Important fundamental numbers of Inox wind
| CMP | ₹164 |
| 52 Week High/Low | ₹177 / 28.7 |
| Stock PE | – |
| ROE | -1.71 % |
| ROCE | 4.25 % |
| Debt to Equity ratio | 1.91 |
| Promoter holding/ Pledge percentage | 52.87% / 1.80 % |
Concord Biotech
Biopharma and API company Concord biotech may see a block deal worth Rs 468.40 crore at Rs 1320 per share. The seller Ontario Inc may offload 3.4% equity. (Source – CNBC TV18)
Q4FY24 results update
| Revenue | 319(vs 273 YOY) |
| EBITDA | 143 (vs 139 YOY) |
| PAT | 95 (vs 91 YOY) |
| EPS | 9.08 (vs 8.75 YOY) |
Important fundamental numbers of Concord biotech
| CMP | ₹1,441 |
| 52 Week High/Low | ₹1,725 / 900 |
| Stock PE | 49.2 |
| ROE | 21.9 % |
| ROCE | 29.0 % |
| Debt to Equity ratio | 0.01 |
| Promoter holding/ Pledge percentage | 44.1 % / 0.00 % |
Timken India
The company manufactures and distributes anti-friction bearings and mechanical power transmission products across various sectors.
Parent entity Timken Singapore may sell 6.6% equity worth Rs 1775 crore. The floor price may be at the 10.2% discount on the closing price on 27th May, 2024. (Source – CNBC TV18)
Q4FY24 results update
| Revenue | 898 (vs 803 YOY) |
| EBITDA | 210 (vs 160 YOY) |
| PAT | 187 (vs 137 YOY) |
| EPS | 18.80 (vs 13.89 YOY) |
Important fundamental numbers of Timken India
| CMP | ₹3,952 |
| 52 Week High/Low | ₹4,350 / 2,490 |
| Stock PE | 75.8 |
| ROE | 17.6 % |
| ROCE | 23.4 % |
| Debt to Equity ratio | 0.01 |
| Promoter holding/ Pledge percentage | 57.7 % / 0.00 % |
For education purpose only. The views are personal. The investments discussed or recommended in the market analysis, research reports, etc. may not be suitable for all investors. Investors must make their own investment decisions based on their specific investment objectives and financial position and only after consulting such independent advisors as may be necessary. We are not a registered financial advisor or research analyst.